Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:24 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 196,679 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALL Clear all
Recruiting Phase 2 Interventional

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031
View directory record Official record
Conditions
Solid Tumors
Interventions
Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel, Irinotecan, Leucovorin, Oxaliplatin, Fluorouracil
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Bellflower, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 3 Interventional

Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin

NCT00385931
View directory record Official record
Conditions
Hypertension, Hypercholesterolemia, Dyslipidemia
Interventions
Valsartan and simvastatin
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231
View directory record Official record
Conditions
Relapsing Multiple Scelrosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
59
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Nov 2, 2026, 10:24 AM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study

NCT02060331
View directory record Official record
Conditions
Nocturia, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

NCT03603431
View directory record Official record
Conditions
Healthy Volunteer
Interventions
MRG-110, Placebo
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
19 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Nov 2, 2026, 10:24 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality in Obstetric Patients

NCT03495531
View directory record Official record
Conditions
Obstetric Pain, Pain
Interventions
Virtual Reality
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 2 Interventional Results available

Effects of Naltrexone on Nicotine Reinforcement

NCT00270231
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Nov 2, 2026, 10:24 AM EST
Completed No phase listed Observational

CTTI Risk Factors for HABP/VABP Study

NCT02689531
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
7,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phototoxicity Potential of NatrOVA Creme Rinse - 1%

NCT00591331
View directory record Official record
Conditions
Head Lice
Interventions
Spinosad (the active ingredient in NatrOVA), placebo
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

NCT01087502
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
16
States / cities
Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Nov 2, 2026, 10:24 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

NCT00616122
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, methotrexate, sunitinib malate, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 2, 2026, 10:24 AM EST
Completed No phase listed Observational

Clinical Implications of Peripheral Plaque Morphology

NCT00578422
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ivus (Intravascular Ultrasound) of Amputation Specimens, IVUS (Intravascular Ultrasound)
Other · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 2, 2026, 10:24 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The S.A.F.E. Study : Computer-Aided Counseling to Prevent Teen Pregnancy/Sexually Transmitted Diseases (STDs)

NCT00151151
View directory record Official record
Conditions
Pregnancy, Sexually Transmitted Diseases
Interventions
Computer-Assisted Motivational Intervention, Didactic Educational Counseling
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Nov 2, 2026, 10:24 AM EST
Completed Not applicable Interventional

Pilot Study to Evaluate Plasma Treatment of Onychomycosis

NCT01819051
View directory record Official record
Conditions
Onychomycosis
Interventions
MOE Antimicrobial Plasma Treatment System
Device
Lead sponsor
Moe Medical Devices
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Nov 2, 2026, 10:24 AM EST
Active, not recruiting Phase 1 Interventional

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

NCT02157051
View directory record Official record
Conditions
HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o

NCT03636451
View directory record Official record
Conditions
Abortion, Spontaneous, Abortion in First Trimester, Pain Uterus, Abortion Early, Abortion, Missed
Interventions
40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block, 20cc 1% lidocaine with 2 units of vasopressin paracervical block
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Nov 2, 2026, 10:24 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women

NCT07215351
View directory record Official record
Conditions
Constipation, Bloating
Interventions
Dietary supplement for digestive health, placebo capsule
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 2, 2026, 10:24 AM EST
Completed No phase listed Observational Results available

Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

NCT01517529
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Nov 2, 2026, 10:24 AM EST
Approved For Marketing No phase listed Expanded access

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

NCT00094029
View directory record Official record
Conditions
Gastrointestinal Neoplasm
Interventions
Sutent
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
32
States / cities
Duarte, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 1 Interventional

Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications

NCT01633229
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Bone Marrow Stromal Cell Infusion
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986365, Rabeprazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of Intravenous Artesunate

NCT00292929
View directory record Official record
Conditions
Malaria, Malaria, Cerebral
Interventions
Intravenous artesunate
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Nov 2, 2026, 10:24 AM EST
Terminated Not applicable Interventional

Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

NCT00728429
View directory record Official record
Conditions
Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
exercise intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 2, 2026, 10:24 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Abdominal aBscess Catheter Sclerotherapy (ABCS)

NCT06906029
View directory record Official record
Conditions
Abdominal Abscess
Interventions
Catheter Sclerotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 2, 2026, 10:24 AM EST